Literature DB >> 25841300

Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin.

Man-man Wang1, Shuo Lin1, Yan-ming Chen1, Jiong Shu1, Hong-yun Lu2, Yong-jun Zhang3, Ru-ying Xie1, Long-yi Zeng1, Pan-wei Mu4.   

Abstract

This study compared the effects on glycaemic variability and glucose control between saxagliptin and acarbose as add-on therapies for aged T2DM inadequately controlled with metformin alone. The results showed that compared with acarbose-metformin, saxagliptin-metformin was more effective in glucose control with similar glycaemic variability.
Copyright © 2015 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Acarbose; Glycaemic variability; Saxagliptin; Type 2 diabetes mellitus

Mesh：

Substances：

Year:  2015        PMID： 25841300     DOI： 10.1016/j.diabres.2015.02.022

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  5 in total

Review 1.  Glycemic Variability: How to Measure and Its Clinical Implication for Type 2 Diabetes.

Authors:  Guillermo E Umpierrez; Boris P Kovatchev
Journal:  Am J Med Sci       Date:  2018-10-02       Impact factor: 2.378

2.  Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study.

Authors:  Guoli Du; Wanrun Xie; Yinxia Su; Yao Ma; Xiaoming Gao; Sheng Jiang; Huazheng Liang
Journal:  PeerJ       Date:  2020-10-02       Impact factor: 2.984

Review 3.  Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China.

Authors:  Shuyan Gu; Yuhang Zeng; Demin Yu; Xiaoqian Hu; Hengjin Dong
Journal:  PLoS One       Date:  2016-11-22       Impact factor: 3.240

4.  Saxagliptin Induces β-Cell Proliferation through Increasing Stromal Cell-Derived Factor-1α In Vivo and In Vitro.

Authors:  Chun-Jun Li; Bei Sun; Qian-Hua Fang; Min Ding; Yun-Zhi Xing; Li-Ming Chen; De-Min Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-27       Impact factor: 5.555

5.  Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Fang Zhang; Shishi Xu; Lizhi Tang; Xiaohui Pan; Nanwei Tong
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-05       Impact factor: 5.555
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.